Euthymics BioScience, Inc. Report issue

For profit Phase 3
Founded: Cambridge MA United States (2009)
Status: Acquired by Ethismos (2017)

Organization Overview

First Clinical Trial
2011
NCT01318434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Euthymics BioScience, Inc. (0) Acquired (2)

amitifadine (2 trials)

bicifadine (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 5
  • # of Trial APIs: 2